Chieh-Lung Cheng

7PUBLICATIONS
11CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)AutoimmunityPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Dec 09, 2025
Time to progression is a simple and robust prognostic factor for survival in relapsed or refractory diffuse large B-cell lymphoma.

Chieh-Lung Cheng, Tai-Chung Huang, Yu-Hsuan Tuan

|Jul 18, 2024
Unraveling the role of hepatitis B virus DNA integration in B-cell lymphomagenesis.

Chieh-Lung Cheng, You-Yu Lin, Chia-Lang Hsu

|Jan 05, 2023
Long-term outcomes of combined intravitreal methotrexate and systemic high-dose methotrexate therapy in vitreoretinal lymphoma.

Chieh-Lung Cheng, Po-Ting Yeh, Wei-Quan Fang

|Dec 08, 2022
Cerebrospinal fluid soluble programmed death-ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma.

Chieh-Lung Cheng, Chi-Yuan Yao, Po-Hao Huang

|Jul 06, 2021
Hepatitis B surface antigen positivity is associated with progression of disease within 24 months in follicular lymphoma.

Chieh-Lung Cheng, Wei-Quan Fang, Yu-Jen Lin

|Apr 11, 2020
Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.

Chieh-Lung Cheng, Sheng-Chuan Huang, Jia-Hong Chen

Pageof 2

Frequent Collaborators

1 joint publications

Chi-Yuan Yao

1 joint publications

Wei-Quan Fang

1 joint publications

Shan-Chi Yu

1 joint publications

Po-Ting Yeh